Kymera Therapeutics, Inc. (KYMR)

Listed in the US · Manufacturing · Biological products, (no diagnostic substances)

$122.60

As of 29 Oct 2026 close.

Facts from reported results and exchange filings. Not investment advice.

Share price

Prices load here as you scroll to them.

Last close $122.60 on 29 Oct 2026. The share price traded between $55.66 and $130.05 (intraday) over the last 12 months.

The closes as a table

DateClose

Key figures

1-year range (intraday)

Last close $122.60

Low $55.66High $130.05

Market cap$10.2Blast close × shares
Net profit$323Mlast 12 months
Return on equity−19.7%year to Dec 2025
EBITDA margin−869.9%year to Dec 2025
Net margin−794.1%year to Dec 2025
Dividend yieldnonelast 12 months

Revenue is very small next to this company's costs or profit, so its margins here are extreme figures (beyond ±100%). They are what the reported numbers give, but they say little about how the business earns.

Price trend

Revenue and profit

RevenueNet profit$ million
-400-300-200-1000100
YearDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue7347794739
Net profit-100-155-147-224-311
EBITDA margin-134.7%-338.0%-206.1%-540.2%-869.9%

$ million. Over three years, compounded: revenue fell 5.7% a year.

Recent filings

Questions about Kymera Therapeutics, Inc.

What is Kymera Therapeutics, Inc.'s market value?

Kymera Therapeutics, Inc.'s market value is $10.2B as of 29 Oct 2026 close: the last close times the shares in issue.

Go further with KYMR

Free to start: test a trading idea on KYMR's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.

Same industry

The largest companies in the same industry (Biological products, (no diagnostic substances)), by market value.

Browse companies

The companies before and after this one, A to Z, and the lists it is in.

How these figures are worked out

The net profit for the last 12 months is the four latest reported quarters, so it can differ from the newest year's in the table below.